Izibhedlela zase-University College London Hospital (UCLH) zimemezele ukuthi zizokwehlisa amandla anti ukuqulwa kwecala Covid-19. Isimemezelo sangomhla zingama-25 kuZibandlela wezi-2020 sithi ''Imithamo ye-UCLH kuqala isiguli emhlabeni ekuhlolweni kwe-antibody ye-Covid-19''futhi'' Abacwaningi ocwaningweni lwe-STORM CHASER oluholwa ngudokotela wezifo zegciwane e-UCLH uDkt Catherine Houlihan baqashe umuntu wokuqala obambe iqhaza emhlabeni kulolu cwaningo.'' (1).
I-antibody engaphansi kokuhlolwa komtholampilo e-UCLH yi-AZD7442 okuyinhlanganisela ye-monoclonal ama-antibodies (mAbs) ithuthukiswe ngabakwa-AstraZeneca. Le nhlanganisela isivele yenza izivivinyo zomtholampilo e USA kusukela ngoDisemba 2, 2020 (2) . Amanye 'amasosha omzimba' amaningana kanye 'nama-antibody cocktails' ahlolwa emitholampilo kwenye indawo (3). Inhlanganisela yamasosha omzimba ku-AZD7442 ashintshiwe ukuze andise ingxenye yempilo yawo ukuze akwazi ukuvikeleka izinyanga eziyisithupha kuya kweziyi-12. Okubaluleke nakakhulu, zenzelwe ukunciphisa ukubopha kwe-Fc receptor okuhloswe ukunciphisa ingozi yokuncika kwe-antibody yesifo-isenzakalo lapho amasosha omzimba egciwane ekhuthaza khona, kunokuba avimbele ukutheleleka. (4).
Lawa ma-antibodies ayithuluzi elibalulekile lokuhlinzeka ngokuvikeleka ezigulini ezinezivikeli mzimba ezibuthakathaka nalapho isifo sesiqhubekele kude. (3). Imithi hlinzeka ngokuzivikela okusebenzayo, nokho ukuthuthukiswa kokuzivikela komzimba ngemithi yokugoma kungase kuthathe isikhathi futhi kungase kungasebenzi ngemva kokuba ukutheleleka sekutholakele. Ukunikeza ukuvikeleka okungenzi lutho ngokusebenzisa ama-antibody asenziwe ngomumo, kuyindlela eya phambili yokunikeza ukuvikeleka okusheshayo ezigulini ezisengozini yokuzivikela ezifweni kanye neziguli ezinesifo esifuthelwa ngokugcwele.
Kuhlelwe izifundo ezimbili. Ucwaningo lwe-STORM CHASER luhlose ukuhlola ukusebenza kahle kwe-monoclonal antibody AZD7442 ukuze kuvikelwe ngokushesha abantu abasanda kuvezwa igciwane le-SARS-CoV-2, ukuvimbela ukuthi bangenwe yi-Covid-19; kanti olunye ucwaningo oluyi-PROVENT luhlose ukuhlola i-antibody AZD7442 kubantu abaye basengozini. i-immune uhlelo abangeke baphendule emithini yokugoma noma abasengozini enkulu ngenxa yezinto ezinjengobudala nezimo ezikhona.
Olunye ucwaningo kanye nophenyo lomtholampilo olusebenzisa inhlanganisela ehlukene yamasosha omzimba angathathi hlangothi egciwaneni le-SARS-CoV-2 luzovula indlela yokuhlinzeka ngokuvikeleka hhayi kubantu abasengozini kuphela abanamasosha omzimba abuthaka kanye nabantu abanalesi sifo kodwa futhi kuzovikela abantu abanempilo ngaphandle kokungenwa igciwane. lesi sifo uma siphathwa ngala masosha omzimba.
***
I-athikili ehlobene: Izinhlobo Ezintsha Ze-SARS-CoV-2 (igciwane elibhekele i-COVID-19): Ingabe Indlela 'Ye-Neutralising Antibodies' ingaba Yimpendulo Yokuguquka Okusheshayo?
***
References:
- UCLH 2020. Izindaba. I-UCLH imithamo yesiguli sokuqala emhlabeni esivivinyweni se-antibody se-Covid-19. Ishicilelwe ngomhla ka-25 Disemba 2020. Itholakala ku-inthanethi kokuthi https://www.uclhospitals.brc.nihr.ac.uk/news/uclh-doses-first-patient-world-covid-19-antibody-trial Kufinyelelwe ngomhlaka-26 Disemba 2020.
- I-NIH 2020. ISigaba III Esingahleliwe, esingaboni kabili, esilawulwa yi-Placebo, esisezindaweni eziningi esicwaningweni kubantu abadala ukuze sithole ukuphepha nokusebenza kahle kwe-AZD7442, Umkhiqizo Oyinhlanganisela Wama-Monoclonal Antibodies Amabili (AZD8895 kanye ne-AZD1061), Ye-Post-Exposure Exposure of Prophylaxia I-COVID-19. Itholakala ku-inthanethi ngo https://clinicaltrials.gov/ct2/show/study/NCT04625972 Kufinyelelwe ngomhlaka-26 Disemba 2020.
- I-Prasad U., 2020. Izinhlobo Ezintsha ze-SARS-CoV-2 (igciwane elibhekele i-COVID-19): Ingabe Indlela 'Ye-Neutralising Antibodies' ingaba Yimpendulo Yokuguquka Kwezinguquko Ezisheshayo?. I-Scientific European Ishicilelwe zingama-23 kuZibandlela 2020. Itholakala ku-inthanethi ku- http://scientificeuropean.co.uk/new-strains-of-sars-cov-2-the-virus-responsible-for-covid-19-could-neutralising-antibodies-approach-be-answer-to-rapid-mutation/ Kufinyelelwe ngomhlaka-26 Disemba 2020.
- I-AstraZeneca 2020. Ukukhululwa kwabezindaba. Inhlanganisela ye-COVID-19 Long-Acting AntiBody (LAAB) i-AZD7442 ithuthukela ngokushesha ekuhlolweni komtholampilo kweSigaba III. Ishicilelwe 09 October 2020. Itholakala ku-inthanethi ku- https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html Kufinyelelwe ngomhla ka-26 Disemba 2020
***
